IGM BIOSCIENCES INC (IGMS) Stock Price, Quote, News and Overview
NASDAQ:IGMS - Nasdaq - US4495851085 - Common Stock - Currency: USD
IGMS Quote, Performance and Key Statistics
1.12
+0.04 (+3.7%)
The current stock price of IGMS is 1.12 USD. In the past month the price decreased by -11.81%. In the past year, price decreased by -82.17%.
IGMS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.07 | 327.88B | ||
| AMGN | AMGEN INC | 13.45 | 150.13B | ||
| GILD | GILEAD SCIENCES INC | 14.32 | 137.91B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 114.33B | ||
| REGN | REGENERON PHARMACEUTICALS | 11.85 | 56.68B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 42.52B | ||
| ARGX | ARGENX SE - ADR | 95.86 | 33.66B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.18 | 26.19B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.59B | ||
| NTRA | NATERA INC | N/A | 23.07B | ||
| BIIB | BIOGEN INC | 7.94 | 18.40B | ||
| INSM | INSMED INC | N/A | 18.33B |
Related stock screener links
About IGMS
Company Profile
IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. The company is headquartered in Mountain View, California and currently employs 149 full-time employees. The company went IPO on 2019-09-18. The firm is engaged in developing and delivering a new class of medicines to treat patients with cancer and autoimmune and inflammatory diseases. The Company’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites compared to conventional IgG antibodies with only two binding sites. The company is also focused on creating, developing, manufacturing, and commercializing IgM antibody agonists against oncology and immunology and inflammation targets. The Company’s development programs include Aplitabart, Imvotamab, and IGM-2644. Aplitabart is an IgM antibody targeting Death Receptor 5 (DR5) proteins, being evaluated in multiple phase I combination trials for the treatment of colorectal cancer. Imvotamab is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins. IGM-2644 is a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins.
Company Info
IGM BIOSCIENCES INC
325 E Middlefield Rd
Mountain View CALIFORNIA 94043 US
CEO: Fred Schwarzer
Employees: 149
Phone: 16509657873
IGM BIOSCIENCES INC / IGMS FAQ
What is the stock price of IGM BIOSCIENCES INC today?
The current stock price of IGMS is 1.12 USD. The price increased by 3.7% in the last trading session.
What is the ticker symbol for IGM BIOSCIENCES INC stock?
The exchange symbol of IGM BIOSCIENCES INC is IGMS and it is listed on the Nasdaq exchange.
On which exchange is IGMS stock listed?
IGMS stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for IGM BIOSCIENCES INC stock?
10 analysts have analysed IGMS and the average price target is 1.72 USD. This implies a price increase of 53.68% is expected in the next year compared to the current price of 1.12. Check the IGM BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is IGM BIOSCIENCES INC worth?
IGM BIOSCIENCES INC (IGMS) has a market capitalization of 67.33M USD. This makes IGMS a Micro Cap stock.
How many employees does IGM BIOSCIENCES INC have?
IGM BIOSCIENCES INC (IGMS) currently has 149 employees.
What are the support and resistance levels for IGM BIOSCIENCES INC (IGMS) stock?
IGM BIOSCIENCES INC (IGMS) has a resistance level at 1.22. Check the full technical report for a detailed analysis of IGMS support and resistance levels.
Is IGM BIOSCIENCES INC (IGMS) expected to grow?
The Revenue of IGM BIOSCIENCES INC (IGMS) is expected to grow by 132.31% in the next year. Check the estimates tab for more information on the IGMS EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy IGM BIOSCIENCES INC (IGMS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of IGMS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of IGMS, evaluating the profitability, health, valuation and growth aspects
- IGM BIOSCIENCES INC (IGMS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- IGM BIOSCIENCES INC (IGMS) Sales and EPS estimates to see what analysts future expectations are.
- IGM BIOSCIENCES INC (IGMS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- IGM BIOSCIENCES INC (IGMS) Insider and Institutional Ownership to learn about the owners and their transactions.
- IGM BIOSCIENCES INC (IGMS) Stock Chart to make your own analysis
- IGM BIOSCIENCES INC (IGMS) Latest news and press-releases to stay up to date.
Does IGM BIOSCIENCES INC (IGMS) stock pay dividends?
IGMS does not pay a dividend.
When does IGM BIOSCIENCES INC (IGMS) report earnings?
IGM BIOSCIENCES INC (IGMS) will report earnings on 2025-08-12, after the market close.
What is the Price/Earnings (PE) ratio of IGM BIOSCIENCES INC (IGMS)?
IGM BIOSCIENCES INC (IGMS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.92).
What is the Short Interest ratio of IGM BIOSCIENCES INC (IGMS) stock?
The outstanding short interest for IGM BIOSCIENCES INC (IGMS) is 3.58% of its float. Check the ownership tab for more information on the IGMS short interest.
IGMS Technical Analysis
IGMS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to IGMS. The financial health of IGMS is average, but there are quite some concerns on its profitability.
IGMS Financial Highlights
Over the last trailing twelve months IGMS reported a non-GAAP Earnings per Share(EPS) of -2.92. The EPS increased by 32.25% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -96.12% | ||
| ROE | -28491.55% | ||
| Debt/Equity | 0 |
IGMS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 48% to IGMS. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of 66.55% and a revenue growth 132.31% for IGMS